Hypercortisolism in Type 2 Diabetes with Treatment-Resistant Hyperglycemia: A Treatable Metabolic Phenotype?

Ji Cheol Bae

doi:10.3803/EnM.2026.3196

Articles

Page Path: HOME > Endocrinol Metab > Volume 41(4); 2026 > Article

Editorial Diabetes, obesity and metabolism Hypercortisolism in Type 2 Diabetes with Treatment-Resistant Hyperglycemia: A Treatable Metabolic Phenotype?: Ji Cheol Bae; Endocrinology and Metabolism 2026;41(4):539-542.
DOI: https://doi.org/10.3803/EnM.2026.3196
Published online: August 12, 2026

Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

Corresponding author: Ji Cheol Bae. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158 Paryong-ro, Masanhoewon-gu, Changwon 51353, Korea, Tel: +82-55-233-5831, Fax: +82-55-233-5109, E-mail: drkuri10@gmail.com

• Received: June 20, 2026 • Accepted: July 13, 2026

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,248 Views
41 Download

prev next

Full Article

Download PDF

Article information
References

The primary goal of diabetes treatment is to prevent diabetes-related complications and improve long-term outcomes, and appropriate glycemic control remains central to this aim [1]. In recent years, diabetes management has placed greater emphasis on individualized treatment strategies, including the selection of glucose-lowering agents according to comorbidities and the adjustment of glycemic targets based on patient characteristics [1,2]. Nevertheless, for most adults with type 2 diabetes who do not have severe comorbidities or substantial hypoglycemia risk, a glycated hemoglobin (HbA1c) target of <7.0%, or more stringently <6.5%, remains a commonly used therapeutic goal [1]. Globally, an estimated 589 million adults, corresponding to approximately 11.1% of the adult population, are living with diabetes [3]. However, many patients still do not achieve recommended glycemic targets [4]. This treatment gap is also evident in the Republic of Korea. In a nationwide population-based study using data from the National Health Insurance Service, 60.6% of Korean patients with diabetes achieved HbA1c <7.0%, leaving approximately 40% above this target. In addition, HbA1c ≥8.0% was observed in 16% of patients [5], indicating that many patients have poor glycemic control and may require more intensive evaluation and treatment strategies.

This glycemic treatment gap is unlikely to have a single cause. Behavioral factors, including poor medication adherence, suboptimal dietary control, and physical inactivity, should be assessed first [6,7]. Clinical inertia and treatment mismatch—such as continued reliance on oral glucose-lowering agents despite progressive β-cell failure or overbasalization in the setting of predominant postprandial hyperglycemia—may also contribute to failure to achieve glycemic targets [8,9]. Accordingly, type 2 diabetes with treatment-resistant hyperglycemia should not be viewed simply as a condition that requires the addition of more glucose-lowering medications. Instead, it should be understood as a complex clinical phenotype in which behavioral factors, β-cell dysfunction, insulin resistance, and treatment mismatch overlap. When poor glycemic control persists despite careful assessment and correction of these factors, overlooked but potentially treatable secondary endocrine causes should be considered [10].

Among these secondary endocrine causes, hypercortisolism has long been suspected to be associated with diabetes and obesity [11–13]. However, it has received relatively little attention in patients without overt Cushing syndrome. Abdominal obesity, hyperinsulinemia, and chronic metabolic stress can activate the hypothalamic-pituitary-adrenal axis, leading in some patients to increased cortisol levels or inadequate cortisol suppression after the 1-mg dexamethasone suppression test (DST) [14]. Therefore, in patients with diabetes or obesity who lack typical Cushing features, such findings have often been interpreted as false-positive DST results, pseudo-Cushing states, or functional hypercortisolism rather than pathologic cortisol excess [15]. This traditional interpretation may have underestimated the clinical relevance and therapeutic potential of non-overt hypercortisolism.

In this context, the CATALYST study provides a useful basis for reevaluating the clinical significance of hypercortisolism in type 2 diabetes with treatment-resistant hyperglycemia. CATALYST was conducted in two parts (Table 1) [16,17]. In the first prevalence phase, patients with difficult-to-control type 2 diabetes, defined as HbA1c 7.5%–11.5% despite multiple glucose-lowering therapies, underwent a 1-mg overnight DST. Hypercortisolism was defined as a post-DST cortisol level >1.8 μg/dL after common causes of false-positive DST results were excluded. Among 1,057 evaluable participants, 252 (23.8%) met the criteria for hypercortisolism. In addition, computed tomography imaging was performed in 219 patients after hypercortisolism was confirmed, and 34.7% had an adrenal abnormality, suggesting that an adrenal source, such as mild autonomous cortisol secretion, may have contributed in some patients [16]. Earlier studies also reported cortisol abnormalities in patients with diabetes or obesity. However, the prevalence of confirmed occult or subclinical hypercortisolism was generally lower, and the study populations were not specifically selected for treatment-resistant hyperglycemia [11–13]. In this respect, the CATALYST findings suggest that hypercortisolism may be more than a nonspecific finding observed in type 2 diabetes and may instead be a potential contributor to the pathophysiology of type 2 diabetes with treatment-resistant hyperglycemia.

The key question, then, is whether hypercortisolism observed in type 2 diabetes with treatment-resistant hyperglycemia represents a treatable metabolic target. CATALYST Part 2 addressed this question by evaluating the glucocorticoid receptor antagonist mifepristone in 136 patients with DST-confirmed hypercortisolism. After 24 weeks, mifepristone significantly reduced HbA1c compared with placebo, and this effect was observed regardless of whether adrenal imaging abnormalities were present. Mifepristone was also associated with reductions in body weight, body mass index, and waist circumference, suggesting that glucocorticoid receptor blockade may affect obesity-related metabolic phenotypes as well as glycemic control [17]. These findings indicate that the hypercortisolism observed in type 2 diabetes with treatment-resistant hyperglycemia may represent a biologically active and therapeutically relevant target. More broadly, they support a shift from focusing only on overt Cushing syndrome to considering a wider spectrum of hypercortisolism, including patients previously categorized as having pseudo-Cushing state or functional hypercortisolism. Recent adrenal incidentaloma guidelines reflect a similar approach: they recommend assessing cortisol-related comorbidities, such as hypertension and type 2 diabetes, in patients with mild autonomous cortisol secretion, with surgery considered as one therapeutic option when these comorbidities are not adequately controlled [18].

Earlier studies attempted to target cortisol-related pathways in type 2 diabetes through 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibition, which reduces local glucocorticoid action in metabolic tissues by blocking the conversion of inactive cortisone to active cortisol. INCB13739, an 11β-HSD1 inhibitor, was evaluated in a 12-week phase 2 study of 302 patients with type 2 diabetes treated with metformin alone, with a mean baseline HbA1c of 8.3%. However, the overall glycemic effect of INCB13739 was modest: even in the high-dose group, the HbA1c reduction was approximately 0.47% [19], and the agent did not achieve clinical success as a diabetes therapy. Other 11β-HSD1 inhibitors were also investigated across various metabolic diseases, but none became established as diabetes therapies [20]. How, then, should the modest effects observed in earlier 11β-HSD1 inhibitor studies be interpreted? In light of the CATALYST findings, the issue may have been patient selection rather than the cortisol-targeted approach itself. Even in the INCB13739 study, greater glycemic effects were observed in subgroups with higher baseline HbA1c or higher body mass index, with HbA1c reductions of approximately 0.65%–0.76% [19]. Earlier studies mainly enrolled general patients with type 2 diabetes or obesity and did not select for cortisol-related phenotypes such as DST non-suppression [20], potentially diluting treatment effects in the overall study population.

In conclusion, hypercortisolism in type 2 diabetes with treatment-resistant hyperglycemia should be viewed as a potentially relevant metabolic phenotype. Recent evidence suggests that non-overt hypercortisolism may, in some patients, contribute to treatment-resistant hyperglycemia. This interpretation moves abnormal cortisol findings away from being viewed solely as false-positive or functional responses and toward recognizing hypercortisolism as therapeutically relevant in a selected subset of patients. Nevertheless, cortisol-targeted therapy is not ready for broad application. Safety concerns [17], including hypokalemia, edema, fatigue, and nausea, together with the need for accurate patient selection, remain major challenges. Future studies should define which patients have clinically meaningful cortisol-driven dysglycemia and determine how cortisol-targeted therapy can be used safely and effectively. If these challenges are addressed, cortisol-targeted approaches may become a useful addition to the therapeutic strategy for type 2 diabetes with treatment-resistant hyperglycemia.

Article information

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Table 1

Summary of the CATALYST Study

Study population	Patients with difficult-to-control type 2 diabetes, defined as an HbA1c level of 7.5%–11.5% despite multiple glucose-lowering therapies
Study objective	To evaluate the prevalence and clinical relevance of hypercortisolism in difficult-to-control type 2 diabetes
Study design	Two-part study consisting of a prevalence phase and a treatment phase
Assessment of hypercortisolism	Hypercortisolism was assessed using the 1-mg overnight dexamethasone suppression test (DST); hypercortisolism was defined as post-DST cortisol >1.8 μg/dL after excluding common causes of false-positive results.
Part 1: main findings	Among 1,057 evaluable participants, 252 (23.8%) met the criteria for hypercortisolism. Computed tomography imaging was performed in 219 patients with confirmed hypercortisolism, and 34.7% had an adrenal abnormality.
Part 2: intervention	Mifepristone, a glucocorticoid receptor antagonist, was compared with placebo in 136 patients with DST-confirmed hypercortisolism (mifepristone, n=91; placebo, n=45).
Part 2: main findings	After 24 weeks, mifepristone significantly reduced HbA1c compared with placebo. The glycemic effect was observed regardless of the presence of adrenal imaging abnormalities, and reductions in body weight, BMI, and waist circumference were also observed.

HbA1c, glycated hemoglobin; BMI, body mass index.

References

1. American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of care in diabetes-2026. Diabetes Care 2026;49(Supplement 1):S132–49.Article PubMed PMC
2. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care 2026;49(Suppl 1):S183–215.Article PubMed PMC
3. Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol 2026;14:149–56.Article PubMed
4. Inoue K, Liu M, Aggarwal R, Marinacci LX, Wadhera RK. Prevalence and control of diabetes among US adults, 2013 to. 2023;JAMA 2025;333:1255–7.Article PubMed PMC
5. Park SE, Ko SH, Kim JY, Kim K, Moon JH, Kim NH, et al. Diabetes fact sheets in Korea. 2024;Diabetes Metab J 2025;49:24–33.Article PubMed PMC PDF
6. American Diabetes Association Professional Practice Committee for Diabetes. 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2026. Diabetes Care 2026;49(Supplement 1):S89–131.Article PubMed PMC
7. Highton PJ, Funnell MP, Gupta P, Zaccardi F, Lim LL, Seidu S, et al. Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes. Diabetologia 2026;69:541–56.Article PubMed PMC PDF
8. Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care; 2018. 41:p. e113–4.Article PubMed PDF
9. Cowart K. Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin. Clin Diabetes 2020;38:304–10.Article PubMed PMC PDF
10. Popoviciu MS, Paduraru L, Nutas RM, Ujoc AM, Yahya G, Metwally K, et al. Diabetes mellitus secondary to endocrine diseases: an update of diagnostic and treatment particularities. Int J Mol Sci 2023;24:12676.Article PubMed PMC
11. Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol 2005;153:837–44.Article PubMed
12. Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003;88:5808–13.Article PubMed
13. Costa DS, Conceicao FL, Leite NC, Ferreira MT, Salles GF, Cardoso CR, et al. Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro type 2 diabetes cohort study. J Diabetes Complications 2016;30:1032–8.Article PubMed
14. Janssen JAMJL. New insights into the role of insulin and hypothalamic-pituitary-adrenal (HPA) axis in the metabolic syndrome. Int J Mol Sci 2022;23:8178.Article PubMed PMC
15. Findling JW, Raff H. Diagnosis of endocrine disease: differentiation of pathologic/neoplastic hypercortisolism (Cushing’s syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing’s syndrome). Eur J Endocrinol; 2017. 176:p. R205–16.Article PubMed
16. Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, et al. Prevalence of hypercortisolism in difficult-to-control type 2 diabetes. Diabetes Care 2025;48:2012–20.PubMed PMC
17. DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, et al. Inadequately controlled type 2 diabetes and hypercortisolism: improved glycemia with mifepristone treatment. Diabetes Care 2025;48:2036–44.PubMed PMC
18. Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2023;189:G1–42.Article PubMed PMC PDF
19. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010;33:1516–22.PubMed PMC
20. Dodd S, Skvarc DR, Dean OM, Anderson A, Kotowicz M, Berk M, et al. Effect of glucocorticoid and 11β-hydroxysteroid-dehydrogenase type 1 (11β-HSD1) in neurological and psychiatric disorders. Int J Neuropsychopharmacol 2022;25:387–98.Article PubMed PMC PDF

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

Cite: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.